{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:10:54Z","timestamp":1789017054574,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Screening out individuals who could benefit from immunotherapy is important in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical records of 199 individuals with unresectable HCC who underwent immunotherapy were retrospectively analyzed. Based on the effect of treatment, individuals were classified into two groups: the response group and the non-response group. NLR, LMR, and CAR were obtained before treatment. Kaplan\u2013Meier method and Cox proportional risk regression model were used for survival analysis, and nomograms were established. A clinical prediction model was developed using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cutoff values of NLR, LMR, and CAR were 5, 1.8, and 0.105, respectively. Individuals with NLR &amp;lt;5, LMR \u22651.8, and CAR &amp;lt;0.105 had higher ORR (43.09% vs. 13.16%, p &amp;lt; 0.001; 57.89% vs. 25.47%, p &amp;lt; 0.001; 41.49% vs. 22.86%, p &amp;lt; 0.01). In the multivariate analysis, it was determined that NLR and CAR independently served as prognostic factors for both PFS and OS. A combined parameter derived from these independent prognostic factors for ORR yielded an area under the curve (AUC) value of prediction probability of 0.825. Notably, the predictive performance of the model surpassed that of NLR (AUC\u00a0=\u00a00.794), LMR (AUC\u00a0=\u00a00.732), and CAR (AUC\u00a0=\u00a00.774).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NLR, LMR, and CAR are potential predictive biomarkers of immunotherapy efficacy in individuals with advanced HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1782572","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:17Z","timestamp":1789014617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomograms and an inflammation model predict immunotherapy prognosis in unresectable hepatocellular carcinoma: from survival and response"],"prefix":"10.3389","volume":"16","author":[{"given":"Er-lei","family":"Zhang","sequence":"first","affiliation":[{"name":"Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ma","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-jia","family":"Du","sequence":"additional","affiliation":[{"name":"Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin Liver Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jhep.2022.10.006","article-title":"Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series' [J Hepatol 73 (2020) 1170-1218","volume":"78","year":"2023","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1744143","article-title":"Liver immunology, immunotherapy, and liver cancers: Time for a rethink","volume":"42","author":"Carroll","year":"2022","journal-title":"Semin Liver Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061370","article-title":"Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment","volume":"9","author":"Pi\u00f1ero","year":"2020","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0466-x","article-title":"Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study","volume":"120","author":"Pinato","year":"2019","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0038-1676806","article-title":"Inflammation and liver cancer: molecular mechanisms and therapeutic targets","volume":"39","author":"Yang","year":"2019","journal-title":"Semin Liver Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-06931-5","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE","volume":"30","author":"Schobert","year":"2020","journal-title":"Eur Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14220","article-title":"The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma","volume":"39","author":"Sanghera","year":"2019","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14797","article-title":"Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma","volume":"8","author":"Personeni","year":"2017","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis","volume":"7","author":"Dolan","year":"2017","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1038\/s41598-022-12058-y","article-title":"C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib","volume":"12","author":"Tada","year":"2022","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3781109","article-title":"Blood biomarkers predict survival outcomes in patients with hepatitis B virus-induced hepatocellular carcinoma treated with PD-1 inhibitors","volume":"2022","author":"Huang","year":"2022","journal-title":"J Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3135","article-title":"Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy","volume":"9","author":"Dharmapuri","year":"2020","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11864-021-00886-5","article-title":"Immunotherapy in hepatocellular carcinoma","volume":"22","author":"Fulgenzi","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.16.3.543","article-title":"Infrequent widespread microsatellite instability in hepatocellular carcinomas","volume":"16","author":"Yamamoto","year":"2000","journal-title":"Int J Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41420-021-00556-3","article-title":"M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p\/YOD1\/YAP\/\u03b2-catenin pathway","volume":"7","author":"Pu","year":"2021","journal-title":"Cell Death Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/187204","article-title":"The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages","volume":"2013","author":"Capece","year":"2013","journal-title":"BioMed Res Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782572\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:26Z","timestamp":1789014626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782572\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1782572"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1782572","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1782572"}}